Trial Profile

Ceftolozane-tazobactam for serious infections caused by Pseudomonas aeruginosa: a real-world experience in Argentina

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceftolozane/tazobactam (Primary)
Indications Bone and joint infections; Nosocomial pneumonia; Pseudomonal infections
Focus Pharmacokinetics

Most Recent Events

27 May 2019 New trial record
16 Apr 2019 Results assessing Ceftolozane-tazobactam for serious infections caused by Pseudomonas aeruginosa presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com